University of Houston Drug Abuse Research Development Program II (UHDARDP-II)
Heroin Dependence
About this trial
This is an interventional treatment trial for Heroin Dependence focused on measuring Opioid Dependence, Injection Drug Use, Hispanics, Mexican Americans, Virtual Reality Cue Exposure
Eligibility Criteria
Inclusion Criteria:
- Injection or Non-Injection heroin user, 3 or more years of heroin use, Hispanic/Latino
Exclusion Criteria:
- Non heroin user, non-Hispanic/Latino, younger than 18 or older than 64, treated with any medications having a potential effect on heroin craving, mood, or heroin cessation medications in the past 30 days; use of other prescription and non-prescription drugs that may affect participation; Fear of closed spaces or inability to wear VR goggles; Visual problems that effect viewing VR materials; History of seizures or seizure disorders; History of serious self-reported health problems; and women who are pregnant
Sites / Locations
- University of Houston Virtual Reality Clinical Research LabRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)
Control: Relapse Prevention Drug Education
Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).